Is Semaglutide a Daily Injection? Weekly Dosing Explained

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is administered as a once-weekly subcutaneous injection, not a daily medication. The standard protocol begins with a 0.25 mg dose and escalates every four weeks based on tolerance and clinical response, with most patients reaching maintenance doses between 1.0 and 2.4 mg weekly.

For individuals considering semaglutide, understanding the actual dosing frequency and escalation timeline is crucial for treatment adherence and provider communication. PlexusDx focuses on precision-guided treatment planning, which includes exploring how your genetic background in peptide-signaling pathways may contextualize your expected dose progression and metabolic response.

Weekly Dosing Protocol: How Semaglutide Scheduling Works

Semaglutide uses a four-week titration schedule, advancing from 0.25 mg to 0.5 mg, then 1.0 mg, and potentially 1.7 mg or 2.4 mg depending on clinical indication and individual response. Each weekly injection provides seven days of GLP-1 receptor stimulation, which explains why daily dosing is neither required nor used in standard protocols.

The weekly frequency simplifies adherence and reduces injection burden compared to daily alternatives. Research indicates that sustained GLP-1 activation via weekly dosing produces more consistent appetite suppression and metabolic effects than shorter-acting daily formulations, making the seven-day interval a pharmacologically intentional design.

Semaglutide Versus Other GLP-1 Medications: Injection Frequency Comparison

Multiple GLP-1 options exist with different dosing schedules. Understanding how semaglutide's weekly protocol compares to alternatives helps clarify which option aligns with your lifestyle and clinical profile.

GLP-1 Medication	Injection Frequency	Dose Range	Administration Route
Semaglutide (compounded)	Once weekly	0.25–2.4 mg	Subcutaneous injection
Tirzepatide (compounded)	Once weekly	2.5–15 mg	Subcutaneous injection
Liraglutide	Once daily	0.6–3.0 mg	Subcutaneous injection
Oral semaglutide	Once daily	3–14 mg	Oral tablet
Dulaglutide	Once weekly	0.75–4.5 mg	Subcutaneous injection

Titration Schedules and Individual Dose Progression

Not all patients reach the same maintenance dose. Titration typically advances every four weeks, but some individuals stabilize at lower doses while others progress to higher therapeutic levels. Clinical response, gastrointestinal tolerance, and metabolic goals guide this progression.

Genetic factors in GLP-1 receptor expression and signaling may influence how quickly your body responds to dose escalation. Your provider adjusts based on observed efficacy and side-effect profile rather than a predetermined maximum, meaning the actual timeline and final dose are highly individualized.

What to Know Before Starting: Safety, Eligibility, and Provider Guidance

Semaglutide is appropriate for individuals with type 2 diabetes or approved weight-loss indications and requires ongoing provider oversight. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. A qualified healthcare provider must assess your complete medical history before initiating therapy.

Starting semaglutide involves explicit informed consent about gastrointestinal side effects, injection technique, storage requirements, and the importance of gradual dose escalation. Regular follow-up appointments allow your provider to evaluate efficacy, monitor for adverse effects, and make evidence-based adjustments to your treatment plan.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in key GLP-1 and GIPR signaling variants such as GIPR rs1800437. These genetic markers may help provide context for understanding individual variability in GLP-1 receptor sensitivity and dose escalation patterns, though genetic predisposition alone does not predict exact medication response.

The genetic test reveals inherited predispositions in peptide pathways relevant to semaglutide's mechanism of action. A genetic profile suggesting lower GLP-1 receptor expression, for example, might contextualize why some patients require higher doses or experience different efficacy timelines—information that should be interpreted collaboratively with your healthcare provider.

Combining genetic insight with clinical assessment, dose response, and biomarker monitoring supports a more informed conversation with your provider about your individual treatment trajectory. This precision-wellness approach helps align your expected dose progression and treatment expectations with your unique biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Why is semaglutide given once a week instead of every day?

Each weekly injection provides seven days of GLP-1 receptor stimulation, so daily dosing is neither required nor used in standard protocols. The article describes the seven-day interval as a pharmacologically intentional design that simplifies adherence and reduces injection burden. It also says sustained activation through weekly dosing produces more consistent appetite suppression and metabolic effects than shorter-acting daily formulations.

Which GLP-1 options in the comparison table are taken daily rather than weekly?

Two entries in the table are daily: liraglutide, given as a subcutaneous injection in a 0.6 to 3.0 mg range, and oral semaglutide, taken as a tablet in a 3 to 14 mg range. The weekly entries are compounded semaglutide, compounded tirzepatide and dulaglutide, all subcutaneous. The table is a comparison of schedules, not a recommendation about which one suits you.

What determines whether someone stops at 1.0 mg or continues up to 2.4 mg weekly?

Clinical response, gastrointestinal tolerance and metabolic goals guide how far the titration progresses. The article says not all patients reach the same maintenance level, with some stabilizing lower while others move to higher therapeutic levels. The provider adjusts based on observed effect and side-effect profile rather than a predetermined maximum, so the final dose and timeline are highly individualized.

Which medical histories rule out starting semaglutide?

The article lists a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy as contraindications. It adds that semaglutide is intended for people with type 2 diabetes or an approved weight-loss indication and requires ongoing provider oversight. A qualified healthcare provider has to assess your complete medical history before therapy begins.

What should a first semaglutide appointment cover before treatment starts?

The article describes explicit informed consent covering gastrointestinal side effects, injection technique, storage requirements and the importance of gradual dose escalation. It also expects regular follow-up appointments so the provider can evaluate how well the medication is working, watch for adverse effects and make evidence-based adjustments. That oversight is presented as part of the treatment, not an optional extra.

Related Reading

• Injection Semaglutide
• Semaglutide Injection
• Semaglutide Dosing
• Medvi Semaglutide

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.